International Journal of Information Technology and Computer Science(IJITCS)

ISSN: 2074-9007 (Print), ISSN: 2074-9015 (Online)

Published By: MECS Press

IJITCS Vol.10, No.6, Jun. 2018

Drugs Relationship Discovery using Hypergraph

Full Text (PDF, 609KB), PP.54-63

Views:49   Downloads:3


Shalini R, Mohan R

Index Terms

Hypergraph;banned drugs;generic drugs;database;data modeling;drug relationship


Globally, the governments are concerned for saving human life but in recent days, the cost of medicine to save the human life grows rapidly, due to the different combination of the drugs sold by the drug store and based on the drugs availability in the drug store. As a regular routine, the Clinical physicians prescribe the drug name or druggist company name for the patient, instead of prescribing the brand name. For a particular drug name, more number of brand name both generic drugs and combination drugs were available. Almost all the physicians or druggist knows these generic drugs and combination drugs along with their dosage and recommends it for the patient. Since the patients are unaware about the brand name of the medicine, they are buying the costly drug without knowledge. At the same time the patients whoever provide the review on the drug consumed, mostly gives a negative review. On the other side, Government gives approval for every drug produced year by year and those drugs getting rejected for approval where sent for new alternative extension of chemical formula, as well government bans several combinations of drugs. There should be a database for awareness; it should help physicians, druggist and end user to look for banned and unbanned drug. We have identified that the drug details and their approvals were not maintained in the database. So, the proposed work is (i) to identify and classify the exact drug, which can be used as generic or combination and (ii) to create a banned drug model representation, which was unavailable. 

A hypergraph-based model named Drugs Relationship Discovery using Hypergraph (DRDH) was constructed as a preliminary design representation for drugs. Here, the drugs combination was considered as a hypervertex and the combination approved for manufacturing in the particular company was considered as an edge, having weight as the price of single dose usage based on Indian government listed drug. With this proposed model as a reference, the banned drugs are listed separately, manufacturing stopped drugs are highlighted with the weight of -1 and the physician or druggist can access the model to ensure the correct drug, their production, and usage. The Time complexity has been analyzed for the hypergraph, which was constructed based on the details of relationship identified among the drugs. Using the parameters of the list of drugs used in India on fever and the common cold, comparison over time taken to identify the relationship has also been done.

Cite This Paper

Shalini R, Mohan R, "Drugs Relationship Discovery using Hypergraph", International Journal of Information Technology and Computer Science(IJITCS), Vol.10, No.6, pp.54-63, 2018. DOI: 10.5815/ijitcs.2018.06.06


[1]Amani Naser Tahat, Maurice HT Ling, “Mapping Relational Operations onto Hypergraph Model”, The Python Papers volume 6, Issue 1, pp: 4, 2017, arXiv: 1105.6118 [cs.DB]. 

[2]BekaErgemlidze, Ervin Győri, Abhishek Methuku, “Asymptotics for Tur´an numbers of cycles in 3-uniform linear hypergraphs, 2017, arXiv preprint arXiv:1705.03561, doi:10.1016/j.endm.2017.06.064.

[3]Ministry of Health and Family Welfare of India online portal for National Health as Digital Initiatives, 2017, 

[4]SamadhanGhubade, Krishna Asvalayan, SharayuParanjpe, Kushagra Gupta and Anil Gore, “On shapes of ADR report accumulation data banned drugs”, Current Science, Volume 113, Issue 9, 10, pp. 1664-1667, 2017, doi:10.18520/cs/v113/i09/1664-1667.

[5]Drugs Control Department under Directorate of Health Services of India Portal, 2017, 

[6]JinalPatel, “Different Data Structures Used for Playing with Anagram”, International Journal of Advance Engineering and Research Development, Volume 2, Issue 5, pp 243-249, 2015, doi:10.21090/ijaerd.020533. 

[7]Suzanne Dunne, Bill Shannon, Colum Dunne and Walter Cullen, “A review of the differences and similarities between generic drugs and their originator counterparts, including economic benefits associated with usage of generic medicines, using Ireland as a case study”, BMC PharmacolToxicol, Volume 14 Issue 1, pp.1-19, 2013, doi:10.1186/2050-6511-14-1. 

[8]Jessy Shaji and Shital Lodha, “Regulatory Status of Banned Drugs in India”, Indian Journal of Pharmaceutical Education and Research, Volume 44 Issue 1, pp. 86-94, 2010. 

[9]Manjari Gupta, Anil Ghom, FM debta, Sunil Vyas, Abhijeet Deoghare, Prashant Gupta, Shantala Gupta, “Banned Drugs: still available in India”, Journal of Indian Academy of Oral Medicine and Radiology, Volume 23 Issue 3, pp. S380-381, 2010, doi:10.5005/jp-journals-10011-1174. 

[10]Alice Iosifescu, Ethan A. Halm, Thomas McGinn, Albert L. Siu, and Alex D. Federman, ” Beliefs about generic drugs among elderly adults in hospital based primary care practices”, Patient EducCouns Volume 73 Issue 2, pp. 377–383, 2008, doi:10.1016/j.pec.2008.07.012. 

[11]Gautam CS, Aditya S, “Irrational drug combinations: need to sensitize under graduate”, Indian Journal Pharmacol, Volume 38, Issue 3, pp.169-70, 2006. 

[12]Tiwary P., Rajshree, “Role of medicine information in promoting rational drug use”, Pharma Times, Volume 38, Issue 7 pp.1-20, 2006. 

[13]Peter Martin, Walter E. Haefeli, Meret Martin-Facklam, “A Drug Database Model as a Central Element for Computer Supported Dose Adjustment within a CPOE System”, Journal of the American Medical Informatics Association, volume 11, Issue 5, pp. 427-432, 2004. 

[14]David A. Papa, Igor L. Markov, “Hypergraph Partitioning and Clustering”, Handbook of Approximation Algorithms and Metaheuristics, pp. 1- 38, 2004, DOI: 10.1201/9781420010749.ch61. 

[15]E.-H. Han, G. Karypis, V. Kumar and B. Mobasher, “Hypergraph Based Clustering in High Dimensional Data Sets: A Summary of Results,” IEEE Bulletin of Technical Committee on Data Engineering, Volume 21 Issue 1, pp. 15-22, 1998.

[16]S Sravika, R Bhavana, V Sharmila, S Anusha, NVN Mounica, D Nagarjuna Reddy and MV Nagabhushanam, “A comprehensive study on regulatory requirements for development and filing of generic drugs globally”, The Pharma Innovation Journal 2017, Volume 6, Issue 4, pp.153-158, 2017. 

[17]Ketaki D. Patil, “Indian Pharma Industry in Global Context: A Statistical Overview”, International Journal of Institutional Pharmacy and Life Sciences, Volume 7, Issue3, p 22-28, 2017.

[18]Varsha Galani,” Choice of Better Medicine in India: Branded Vs Generic Medicine”, Volume 5, Issue 3, pp 1-2, 2017. 

[19]Wei Dua,e, Sallie-Anne Pearson, Nicholas A Buckley, Cathy Daya, Emily Banks, “Diagnosis-based and external cause–based criteria to identify adverse drug reactions in hospital ICD-coded data: application to an Australian population-based study”, Public Health Research & Practice, Volume 27, Issue 2, e2721716, 2017, doi: 

[20]LiveMint E-Paper on “Generic drug approvals in US hit record high in FY17”,, 2017. 

[21]Sandhya V. Kawale, S. M. Kamalapur, "Image Retrieval using Hypergraph of Visual Concepts", International Journal of Information Technology and Computer Science(IJITCS), Vol.9, No.12, pp.38-44, 2017. DOI: 10.5815/ijitcs.2017.12.05

[22]Hepsiba Mabel V, Justus Selwyn,"A Review on the Knowledge Representation Models and its Implications", International Journal of Information Technology and Computer Science(IJITCS), Vol.8, No.10, pp.72-81, 2016. DOI: 10.5815/ijitcs.2016.10.09

[23]Patrick D. Cerna, Thomas Jemal Abdulahi,"Prediction of Anti-Retroviral Drug Consumption for HIV Patient in Hospital Pharmacy using Data Mining Technique", International Journal of Information Technology and Computer Science(IJITCS), Vol.8, No.2, pp.52-59, 2016. DOI: 10.5815/ijitcs.2016.02.07